293,029 Shares in Organogenesis $ORGO Acquired by HighMark Wealth Management LLC

HighMark Wealth Management LLC purchased a new position in Organogenesis (NASDAQ:ORGO) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 293,029 shares of the company’s stock, valued at approximately $1,072,000. Organogenesis accounts for 0.5% of HighMark Wealth Management LLC’s portfolio, making the stock its 24th biggest holding. HighMark Wealth Management LLC owned about 0.23% of Organogenesis at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Farther Finance Advisors LLC purchased a new stake in shares of Organogenesis during the second quarter valued at approximately $35,000. Merit Financial Group LLC acquired a new stake in Organogenesis during the 1st quarter valued at $45,000. Victory Capital Management Inc. purchased a new stake in Organogenesis during the 1st quarter worth $67,000. OMERS ADMINISTRATION Corp acquired a new position in Organogenesis in the 1st quarter worth $77,000. Finally, Ieq Capital LLC purchased a new position in Organogenesis in the 1st quarter valued at about $79,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Stock Performance

Shares of ORGO stock opened at $4.23 on Friday. The stock has a market capitalization of $536.62 million, a price-to-earnings ratio of -30.21 and a beta of 1.68. Organogenesis has a one year low of $2.61 and a one year high of $6.71. The company’s 50-day simple moving average is $4.72 and its 200-day simple moving average is $4.23.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08). Organogenesis had a negative net margin of 1.92% and a negative return on equity of 0.37%. The firm had revenue of $101.01 million during the quarter, compared to the consensus estimate of $104.75 million. Organogenesis has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Organogenesis will post -0.07 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Cantor Fitzgerald lifted their target price on Organogenesis from $7.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. BTIG Research reissued a “buy” rating and issued a $7.00 price target on shares of Organogenesis in a report on Friday, September 26th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.33.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.